HUMAN GENETICS INITIATIVE
|
|
- Morgan Jennings
- 6 years ago
- Views:
Transcription
1 Clinical Protocol HUMAN GENETICS INITIATIVE Ancillary Study to A Comparison of Long-Acting Injectable Medications for Schizophrenia (ACLAIMS) National Institute of Mental Health Grant R01-MH and RO1-MH Version 1.0 February 16, 2010 Principal Investigators: Joseph McEvoy, MD Scott Stroup, MD, Matt Byerly, MD
2 TABLE OF CONTENTS 1 Specific Aims Subjects Persons eligible for this study include participants in the ACLAIMS study. Each site shall seek to enroll all current participants in the parent trial. Only participants, not participants relatives or other subjects, are to be enrolled in this study Inclusion/Exclusion Criteria Methods Blood Sample Collection Generation of Patient IDs Study Supplies Sample Shipping and Processing Human Subjects Issues Duration of study and subject s participation Full description of risks and measures to minimize risks Benefits to subjects and/or society Inducements for participation Costs to be borne by subjects Methods of Recruiting Informed Consent Procedures for Consent Form approval Consent discussion
3 1 SPECIFIC AIMS The Human Genetics Initiative will result in the creation of cell lines of genetic material from the cohorts participating in the A Comparison of Long-Acting Injectable Medications for Schizophrenia (ACLAIMS) study that will be used in future studies to advance knowledge about schizophrenia.. The NIMH Center for Genetics Studies will create high quality lymphoblastoid cell lines to establish an infinitely renewable source of DNA for subsequent genetic analyses. The specific aims of the project are: a) To collect, prepare, and ship adequate blood samples from ACLAIMS participants with schizophrenia to the NIMH Center for Genetics Studies Cell Repository (Repository). b) To ensure that the confidentiality and rights of the participants are protected. 2 SUBJECTS 2.1 Persons eligible for this study include participants in the ACLAIMS study. Each site shall seek to enroll all current participants in the parent trial. Only participants, not participants relatives or other subjects, are to be enrolled in this study Inclusion/Exclusion Criteria Persons who have been randomized to study drug in the parent ACLAIMS trial are eligible to participate in this Human Genetics Initiative. 3 METHODS 3.1 Blood Sample Collection Blood samples will be collected by site personnel during the visit in which consent for the genetics initiative is obtained or the next convenient subject visit (see Methods of Recruiting in Section 5). Two yellow-top and one purple top tube sample tubes of blood will be collected. The tubes will be shipped to the Center for Genetics Studies following the procedures on the Flow Sheet for Blood Sample Procedures 3.2 Generation of Patient IDs A randomly assigned NIMH ID number and ACLAIMS subject ID will be used to track the vials. The NIMH number will be generated by the Collaborative Studies Coordinating Center according to the specifications of NIMH. The ACLAIMS subject ID is a numeric code. Sites will be provided with 4 ID labels with randomly assigned NIMH ID numbers 3 labels for the blood vials and 1 that goes on the NIMH Genetics Initiative: Clinical Trial Off NIHM collection form (NIHM Collection form). A copy of the NIHM collection form will be kept in the Clinical Binder. This will ensure that monitors can check to see if a blood sample was taken based on the label in the source document binder. Subject identities shall be protected because no direct personal identifiers will accompany the blood samples to the Repository. Detailed instructions for labeling, packaging and shipping blood sample tubes are specified in the Flow Sheet for Blood Sample Procedures 3
4 3.3 Study Supplies Sites will be provided with kits that include the necessary materials to collect blood samples. Sites will be provided with materials when they have IRB approval. 3.4 Sample Shipping and Processing Each site will ship blood samples in to the NIMH Repository.The NIMH Center for Genetics Studies will create high quality lymphoblastoid cell lines to establish an infinitely renewable source of DNA for subsequent genetic analyses. After the cell lines have been established, clinical data, without patient identifiers, will be transferred to the NIMH Center for Genetics Studies by the Collaborative Studies Coordinating Center. The data will include clinical, diagnostic, laboratory, and therapeutic response data. The link between the genetic material and ACLAIMS data will be made using the coded ID numbers only. No personal identifiers will be attached to the genetic material. Sites will be required to make one sample shipment (with tubes filled with water) to the NIMH Center for Genetic Studies Cell Repository prior to shipping blood samples. This will establish the acceptability of the site s packing and documentation procedures. 4 HUMAN SUBJECTS ISSUES 4.1 Duration of study and subject s participation ACLAIMS participants will provide a blood sample for the Human Genetics Initiative on one occasion. Enrollment will continue for the duration of enrollment in the parent ACLAIMS study. Participants may be asked to submit a second sample if an adequate cell line is not established from the initial sample. (Cell line transformations are successful approximately 99% of the time at the Center for Genetics Studies. A small proportion of samples may be damaged in shipping.) 4.2 Full description of risks and measures to minimize risks There are no more than minimal medical or psychological risks associated with this research. Some people may experience discomfort, bruising, and/or other bleeding at the site where the needle is inserted. Sometimes people get dizzy or feel faint when their blood is drawn. Subjects will be offered comfort and support. An insurance company might consider participation in the study an indication of higher risk because it implies that there is a family history of a genetic condition. This might then hurt participants access to health or other insurance. If participants tell their doctor about participation in this study, this information may then become part of the medical record with this doctor. Insurance companies routinely have access to such records. We will not release information unless authorized by individual participants. Subject privacy will be ensured by generating unique patient IDs for this study as outlined in the Generation of Patient IDs section above. No data with direct patient identifiers will be sent to the Center for Genetics Studies or to other future researchers. The researchers have obtained a Certificate of Confidentiality from the Federal Government. 4
5 4.3 Benefits to subjects and/or society Subjects will not receive any direct benefit from this project. Individuals who might develop schizophrenia in the future, their family members, and future generations may benefit if genes that lead to such disorders, or genes that predict responses to different medications can be located. 4.4 Inducements for participation It is recommended that subjects be paid $20 for participating in the Human Genetics Initiative. Subjects will not receive any financial benefits from commercial products derived from the data. 4.5 Costs to be borne by subjects There are no costs to subjects for participating in the Human Genetics Initiative. 4.6 Methods of Recruiting The study clinician or study coordinator shall inform already randomized participants of the genetics study during the next scheduled visit after the site is cleared for implementation of the genetics study. Newly enrolling participants in the ACLAIMS trial shall be informed of the Human Genetics Initiative at the Screening Visit and shall be asked to enroll in at the first visit deemed appropriate by the site investigator. Only patients who have been randomized to study drug should participate in the Human Genetics Initiative. Site personnel will be encouraged to contact subjects who have dropped out or completed the study to request their participation in this genetics initiative. Subjects who have withdrawn consent will not be contacted. 4.7 Informed Consent The consent forms used are based on a template provided by the NIMH that are meant to conform to all applicable regulations (Appendix A). The consent form addresses the following: 1. Disclosure that biomaterials (DNA and cell lines) and clinical data (including diagnostic, laboratory, and therapeutic response and adverse event data) will be distributed as a national resource to researchers in the scientific community for genetic analyses; 2. Assurance that such data will be stored and maintained without personal identifiers; 3. Disclosure that analyses of these data will be conducted by other scientists not included on the current research team; 4. Disclosure that there is no plan to provide subjects with any financial benefits from commercial products derived from the data. 5. No plan to inform subjects of individual results. 5 PROCEDURES FOR CONSENT FORM APPROVAL Prior to initiation of data collection and prior to approval to the local IRBs, each Site shall electronically submit to Columbia University its consent form. Columbia University will submit these to NIMH. After approval by the NIMH, the consent form shall be submitted to the local IRBs for approval. The consent form must satisfactorily address items 1-5 above. A template of such a consent form will be provided to each site with highlighted language that should be standard among all sites and therefore should not be modified (Appendix A). 5
6 Within one week of approval by the Site s IRB, the approved consent form and letter of approval must be submitted to Columbia University, who will then submit to New York State Psychiatric Institute IRB and NIMH. Columbia University will notify participating sites when they can begin enrollment. 5.1 Consent discussion The consent discussion between the clinician/study coordinator and the participant shall emphasize: 1. That the decision to participate or not participate in the genetics study shall not affect participation in the parent study, the care received in the trial, or the care otherwise available. 2. That the data and the biomaterials shall be stored without direct patient identifiers so that participant anonymity will be preserved. 3. That the phenotypic data and biomaterials shall ultimately be shared with the scientific community for genetic analysis. 4. That there is no plan to provide subjects with any financial benefits from commercial products derived from the data. 5. That there is no plan to inform subjects of individual results. 6
SUNY Upstate Medical University. Stephen J. Glatt, Ph.D. Stephen V. Faraone, Ph.D
SUNY Upstate Medical University Stephen J. Glatt, Ph.D. Stephen V. Faraone, Ph.D. 315-464-7742 315-464-3113 Study Title: Longitudinal Family/Molecular Genetic Study to Evaluate Research Domain Criteria
More informationGenentech, Inc., its research partners, collaborators, assignees, licensees or designees. Invitation to Participate
CONSENT AND RESEARCH AUTHORIZATION TO DONATE BLOOD AND TISSUE SAMPLES FOR FUTURE RESEARCH PURPOSES YALE UNIVERSITY SCHOOL OF MEDICINE YALE-NEW HAVEN HOSPITAL 200 FR. 4 Study Title: An Open-Label, Phase
More informationAnnex VIIIB Paragraphs to be included in the Informed Consent Form for the collection and use of biological samples in clinical trials
DEPARTAMENTO DE MEDICAMENTOS DE USO HUMANO Annex VIIIB Paragraphs to be included in the Informed Consent Form for the collection and use of biological samples in clinical trials Version 20 th December
More informationNIMH Center for Collaborative Genetic Studies Distribution Agreement
NIMH Center for Collaborative Genetic Studies Distribution Agreement WHEREAS, the National Institute of Mental Health ("NIMH"), pursuant to its public health mission to identify and characterize the genetic
More informationIRB USE ONLY Approval Date: September 10, 2013 Expiration Date: September 10, 2014
Approval : September 10, 2013 Expiration : September 10, 2014 DESCRIPTION: You are invited to donate your excess sperm and/or testicular biopsy material, as well as your somatic cells (ordinary body cells
More informationBrain Tumour Australia Information FACT SHEET 22 Clinical Trials: Questions and Answers
FACT SHEET 22 Clinical Trials: Questions and Answers What is a clinical trial? Clinical trials are research studies that answer scientific questions and try to find better ways to prevent, screen for,
More informationIRB USE ONLY Approval Date: September 10, 2013 Expiration Date: September 10, 2014
Approval : September 10, 2013 Expiration : September 10, 2014 DESCRIPTION: You are invited to donate your leftover frozen eggs and/or ovarian tissues generated during your fertility preservation treatment
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More informationRECRUITING OF AND ADVERTISING FOR SUBJECTS
1. POLICY Steering Committee approved 9/19/11 The informed consent process begins when a potential human research subject first learns of a study, which is usually accomplished through recruitment efforts.
More informationNanthealth Patient Informed Consent
Patient Informed Consent Why am I being asked to give consent? You are being asked to sign this consent form because you want to have a molecular/genomic analysis performed to help your physician understand
More information4.2. Investigator Regulatory Binder: Files, usually a binder, maintained by the investigator at the investigative site.
POLICY #: RCO-203 Page: 1 of 7 1. POLICY STATEMENT: Essential regulatory documents will be on maintained for research sponsored by or conducted at Dana-Farber/Harvard Cancer Center (DF/HCC) to assure compliance
More informationParticipant Copy. No. Participation is voluntary. Your decision will not affect your health care at Mayo Clinic in any way.
Name and Clinic Number IRB # 08-007049 00 Consent form approved July 16, 2015; This consent valid through July 15, 2016; 1. General Information About This Research Study Study Title: Mayo Clinic Biobank
More informationCompliance and Quality Monitoring: What, Why, When, and How
Compliance and Quality Monitoring: What, Why, When, and How Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Research Institute, University
More informationHuman Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents
Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time
More informationROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016
UCLA CTSI WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016 Objectives Define the sponsor of a clinical trial and learn
More informationRequirements for Humanitarian Use Device (HUD)
Requirements for Humanitarian Use Device (HUD) 1. Definition of Humanitarian Use Device - The definition of a HUD is a device that is intended to benefit patients in the treatment and diagnosis of diseases
More informationConsent Language Does Affect Your Ability to Share
Consent Language Does Affect Your Ability to Share Tuesday, February 13, 2018 Jean Barone HRPO Director Melissa Miklos HRPO Associate Director Change in Education Units Continuing Education Units will
More informationESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL
Assemble Essential Documents in Trial Master File (TMF) Appendix 1 ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL 8.2 Before the Clinical Phase of the Trial Commences During this planning stage
More informationRegulatory Document Guidelines for DMID Clinical Studies. Version Oct-2005
Regulatory Document Guidelines for DMID Clinical Studies Version 3.0-5-Oct-2005 1 Regulatory File Document Guidelines Purpose: To aid DMID supported Investigators in establishing a file of essential documents
More informationELEMENTS OF A DATA MONITORING PLAN
ELEMENTS OF A DATA MONITORING PLAN Definitions Data Monitoring: The regular evaluation of data and documentation collected during a study to ensure both adherence to the approved investigative plan and
More informationI. Purpose. II. Definitions. Last Approval Date
Investigational Drugs and Biologics Page 1 of 13 I. Purpose The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics
More information3.1. Overall Principal Investigator (PI), who holds the IDE and/or is the Sponsor
POLICY #: RCO-101 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational Device Exemption (IDE) or who is the Sponsor of the research has additional responsibilities
More informationDevice research sponsors, whether companies or investigators, are held responsible for meeting the same regulations.
POLICY #: RCO-101 Page: 1 of 11 1. POLICY STATEMENT: A DF/HCC Investigator who holds an Investigational Device Exemption (IDE) or who is the Sponsor of the research has additional responsibilities that
More informationHuman Research Protection Program Guidance for Human Research Determination
Human Research Protection Program Guidance for Human Research Determination I.1.A The sole purpose of the Institutional Review Board (IRB), as defined in federal statutes, is the protection of human subjects
More informationShort Title: CCI Biobank
Patient Label Stamp or letterhead of the department Patient Information Donation, Storage and Use of Biological Materials and Collection, Processing and Use of Data of the CCI Biobank, Medical Center -
More informationGUIDELINES FOR TISSUE COLLECTION FOR RESEARCH AUTOPSY
GUIDELINES FOR TISSUE COLLECTION FOR RESEARCH AUTOPSY 1. Informed consent for the above tissue collection can be obtained by: a. Physicians who have completed the CITI/Miami Human Subjects Research Educational
More informationFDA Audit Preparation
Duke University Office of Audit, Risk and Compliance (OARC) FDA Audit Preparation Margaret M. Groves, JD, CRA, CCRP, CHRC Associate Compliance Officer, Research Compliance Assurance (RCA) External audits
More informationRESPONSE TO RFP - Title Page
University of Pennsylvania RESPONSE TO RFP - Title Page Request for Proposal (RFP) Number: 002 Issue Date: July 16, 2008 Proposal Due Date: August 18 2008 Title of RFP: Central Laboratory for a Randomized
More informationStanford University IRB Guidance On Data and Tissue Repositories
Stanford University IRB Guidance On Data and Tissue Repositories Databases, registries (data banks), and repositories (tissue banks) all involve the collection and storage of information and/or biological
More informationRelated Donor Informed Consent to Participate in Research
Related Donor Informed Consent to Participate in Research This is an informed consent document for a research study that your family member is participating in. This document will inform you about the
More informationPatient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies WWW.ISSCR.ORG WWW.CLOSERLOOKATSTEMCELLS.ORG Patient Handbook on Stem Cell Therapies Introduction We have all heard about the extraordinary promise that stem cell
More informationROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Investigational
More informationannex 3. Template consent form for biobanking
annex 3. Template consent form for biobanking This template is based on Public Population Project in Genomics and Society (P3G) database resources. General considerations The information brochure and consent
More information1. POLICY STATEMENT: 2. BACKGROUND:
POLICY #: RCO-201 Page: 1 of 5 1. POLICY STATEMENT: All Food and Drug Administration (FDA) regulated research conducted under an Investigational New Drug Application (IND) and managed within DF/HCC requires
More information07/30/2013. Record of Revisions IRB Page 1 of 17
Current Protocol Version 7.1 (Continuing Review) Approved July 30, 2013 Version 7.1 (Amendment) September 6, 2012 Version 7.0 (Continuing Review) July 30, 2012 Version 6.0 (Continuing Review) July 30,
More informationCorrelative Science and Tissue Banking Procedures. Canadian Cancer Trials Group
Correlative Science and Tissue Banking Procedures Canadian Cancer Trials Group January 31, 2013 Our Policy The Canadian Cancer Trials Group has established a tumour/tissue/data repository to ensure the
More informationPHARMACY, MEDICINES & POISONS BOARD
PHARMACY, MEDICINES & POISONS BOARD PHARMACY GUIDELINES FOR INVESTIGATIONAL DRUGS A. Purpose These guidelines are principally derived and adapted from guidelines from various sources within the SADC region.
More informationHRPP Policy No. 714 Effective Date 09/01/10 Revisions Date. Genome Wide Association Studies
Genome Wide Association Studies HRPP Policy No. 714 Effective Date 09/01/10 Revisions Date 1.0 Purpose This policy describes how investigators at the University of South Florida (USF) and USF Affiliates
More informationInformed Consent Document. Blood Sampling
APPENDIX A2 Case ID # Sample Id # Informed Consent Document Regional Capacity Building Program for Health Risk Management of Persistent Organic Pollutants (POPs) in South East Asia: Blood Sampling 1 TITLE
More informationThe National Cell Repository for Alzheimer s Disease. Kelley Faber, MS, CCRC Colleen Mitchell, BS
The National Cell Repository for Alzheimer s Disease aka NCRAD Kelley Faber, MS, CCRC Colleen Mitchell, BS NCRAD Established in 1990 at Indiana University Recruit families with at least 2 living members
More informationOverview: Simons Simplex Collection
Overview: Simons Simplex Collection What is the Simons Simplex Collection? The Simons Simplex Collection (SSC) is a resource of phenotypic and genetic data and biospecimens for use by autism researchers.
More informationMulti-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18
Multi-Site Coordination Process Drafted by: Ester Dimayuga Page 1 of 18 MULTI-SITE COORDIATIO (MSC) REGULATOR PROCESS CTO-Regulatory notifies MSC of trial with UMCC as coordinating center MSC prepares
More informationClinical trials patient-education brochure
Released November 2005 Revised January 2008 Revised March 2012 Revised July 17, 2017 Clinical trials patient-education brochure Roslyn Mannon, MD David Rothstein, MD Maria Luisa Alegre, MD, PhD Giorgio
More informationIllumina Clinical Services Laboratory
Illumina Clinical Services Laboratory CLIA Certificate No.: 05D1092911 Illumina Clinical Services Laboratory TruGenome Technical Sequence Data Test Requisition Form The Illumina Clinical Services Laboratory
More informationSt. Luke s University Health Network
Page 1 of 5 PURPOSE: This standard operating procedure (SOP) applies to the activities involved in the collection and handling of laboratory specimens from patients enrolled in clinical studies subject
More informationClinical Trial Basics:
Clinical Trial Basics: Components and Responsibilities Pre-Award Aida Nana Ama Manu, Project Coordinator Four Main Components Non-Disclosure Agreements Institutional Review Board Application Clinical Trial
More informationGUIDELINES FOR CONDUCTING CLINICAL TRIALS.
GUIDELINES FOR CONDUCTING CLINICAL TRIALS. FOREWORD The purpose of Drug Registration is to ensure that a pharmaceutical product has been adequately tested and evaluated for safety, efficacy and quality,
More informationResearch Involving Human Data or Specimens
Page 1 of 5 Research Involving Human Data or Specimens Introduction: The Office for Human Research Protections has issued guidance on research involving coded private information or human biological specimens.
More informationTOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH
Investigators Responsibility #1: Design and Implement Ethical Research Consistent with the Three Ethical Principles Delineated in The Belmont Report. The Belmont Report: Three Basic Ethical Principles:
More informationConsent Form. Protocol Title: Personal Genome Project
Consent Form Protocol Title: Personal Genome Project Principal Investigator: George M. Church, Ph.D. Site-Responsible Investigator's Institution: Harvard Medical School Co-Investigators & Study Staff:
More informationFDA Sponsor and Investigator Responsibility Checklist
FDA Sponsor and Investigator Responsibility Checklist Principal Investigator: Study Name: CPHS #: IND/IDE #: Name of IND/IDE holder: The following checklist is created based on the Sponsor and Investigator
More informationHub Performance Assessment
Hub Performance Assessment Hub complex performance assessment will be assessed with a standardized report card mechanism. The report card draws on data quality reports, enrollment reports, and monitoring
More informationProtection of Research Participants: The IRB Process and the Winds of Change
Protection of Research Participants: The IRB Process and the Winds of Change Ethics in Patient-Oriented Research October 12, 2011 Sharon Friend Director, OHRPP Overview Charge and Function of the IRB Quick
More informationSimons Simplex Collection: Recruitment Process
Simons Simplex Collection: Recruitment Process Overview: Simons Simplex Collection What is the Simons Simplex Collection? The Simons Simplex Collection (SSC) is a resource of phenotypic and genetic data
More informationMCW Office of Research Standard Operating Procedure
MCW Office of Research Standard Operating Procedure USE AND STORAGE OF INVESTIGATIONAL DRUGS AND BIOLOGICS Unit: Applies to: Human Research Protections Program (HRPP), Office of Research MCW/FH Faculty
More informationClinical Trials Management for Molecular Diagnostics. April 2016
Clinical Trials Management for Molecular Diagnostics April 2016 Clinical Operations Responsibilities Accrue samples that have proper informed consent for use Retrospective cohorts Remnant samples Prospective
More informationPOST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)
POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) Purpose: Investigators who initiate and submit an IND application to the FDA assume the responsibilities of both the
More informationIND Development Process Published on ResearchGo UCLA (
IND Development Process IND Development Overview The Pre-IND Process The IND Study Protocol Preparing the Initial IND Submission Filing the IND Maintaining the IND IND Templates, Education and Useful Links
More informationRegulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1
Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1 Phone: 650.691.4400 Fax: 650.691.4410 Email: regulatory.ccsainc.com COMPLIANCE & STANDARDIZATION Rationale for Revision of
More informationTitle: Department: Approved by: Director, Human Research Review and Compliance. KEYWORDS: IRB, Institutional Review Board
Title: Department: Research Tissue Banks/ Repositories Human Research Affairs Policy Type: Partners System-wide Partners System-wide Template Partners HealthCare Partners HealthCare Departmental Institution
More informationInvestigational New Drug Development Steps for CRCs
Investigational New Drug Development Steps for CRCs Natalie Nardone, PhD Program Manager, Department of Medicine CRC Instructor, Office of Clinical Research Contact: natalie.nardone@ucsf.edu Learning Objectives
More informationStudy Files and Filing
Study Files and Filing The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.ths.nhs.uk/departments/research/research.htm
More informationSCHOOL OPERATIONS POLICY 5010 PERSONAL INFORMATION PRIVACY POLICY FOR EMPLOYEES AND VOLUNTEERS
SCHOOL OPERATIONS POLICY 5010 PERSONAL INFORMATION PRIVACY POLICY FOR EMPLOYEES AND VOLUNTEERS Catholic Independent Schools of Nelson Diocese, B.C. Approved: November, 2004 Amended: January 31, 2013 St.
More informationObjectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder
Essential Documents: Maintaining the Site's Regulatory Binder How to Manage the Essential Documents for the Investigator and Study Site Objectives Describe the importance of maintaining the Regulatory
More informationPresented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals
ORIENTATION FOR NEW CLINICAL RESEARCH COORDINATORS Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals Overall Agenda for Orientation Module 1: Introduction
More informationRegulatory Binder Guidance
Regulatory Binder Guidance What is the purpose of a regulatory binder? Achieve and maintain regulatory compliance Ensure protection of human subjects and high standards of research Guidance for organization
More informationCHANGES IN STUDY PROCEDURES OR FUNDING: IS A NEW STUDY NEEDED?
CHANGES IN STUDY PROCEDURES OR FUNDING: IS A NEW STUDY NEEDED? PROTOCOL REVISIONS, FUNDING, AND SECONDARY ANALYSIS CONSIDERATIONS Emory University IRB August 10, 2017 Topics to be covered When you are
More informationGuidelines for Setting Up a Regulatory Binder
Guidelines for Setting Up a Regulatory Binder Prepare for an audit Georgamaly Estronza, MS UPR - Medical Sciences Campus IRB Administrator - Compliance Officer Email: georgamaly.estronza@upr.edu Introduction
More informationThe Importance of Participating in Clinical Trials in Alzheimer s Disease. Amanda G. Smith, M.D. Medical Director USF Health Byrd Alzheimer Institute
The Importance of Participating in Clinical Trials in Alzheimer s Disease Amanda G. Smith, M.D. Medical Director USF Health Byrd Alzheimer Institute First and foremost Clinical trials and studies are a
More information11.0 FDA-Regulated Research
11.0 FDA-Regulated Research The HSC evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationFood and Drug Administration Guidance: Supervisory Responsibilities of Investigators
Journal of Diabetes Science and Technology Volume 5, Issue 2, March 2011 Diabetes Technology Society REVIEW ARTICLE Food and Drug Administration Guidance: Supervisory Responsibilities of Investigators
More informationINVESTIGATIONAL DRUG MANAGEMENT OVERVIEW
NORTHWELL HEALTH OFFICE OF RESEARCH COMPLIANCE STUDY FEASIBILITY AND APPROVAL Where can I learn about the investigational drug? Protocol Investigator s brochure Product insert or prescribing information
More information\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management
Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles
More informationInstitutional Review Board for Use of Human and Animal Subjects in Research OIT
OREGON INSTITUTE OF TECHNOLOGY Institutional Review Board for Use of Human and Animal Subjects in Research Introduction No person in the United States should be enrolled in research without the twin protections
More informationFREQUENTLY ASKED QUESTIONS
CLINICAL TRIALS FREQUENTLY ASKED QUESTIONS PARTICIPATING IN A CLINICAL TRIAL What is a clinical trial? Clinical trials are research studies that involve people. Through clinical trials, researchers find
More informationExpanded Access and the Individual Patient IND
Expanded Access and the Individual Patient IND Research Wednesdays April 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office of Regulatory Affairs and Quality Office
More informationISPE Comments on the CIOMS 2006 draft Special Ethical Considerations for Epidemiologic Research 1
Epidemiologic Research 1 December 12, 2006 Comments on 2006 CIOMS draft Special Ethical Considerations for Epidemiologic Research as proposed supplement to the updated 2002 CIOMS International Ethical
More informationRegulatory Binder: Set-up and Maintenance
Regulatory Binder: Set-up and Maintenance Introduction Federal and state regulations, institutional policy, and good clinical and research practices require investigators to maintain documents related
More informationRules of Human Experimentation
Rules of Human Experimentation Elaine Larson CUMC IRB Chair Associate Dean for Research, School of Nursing Professor of Epidemiology, Mailman School of Public Health Oversight for Human Research Office
More information11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationEffective Date: April 19, 2018 TITLE: GUIDELINE FOR RADIATION SAFETY COMMITTEE REVIEW OF HUMAN RESEARCH STUDIES. Table of Contents
Version: 2 Page: 1 of 6 Table of Contents 1.0 Introduction... 2 1.1 Purpose... 2 1.2 Scope... 2 1.3 Definitions... 2 2.0 Initial Protocol Review... 2 3.0 Radiation Risk Language... 3 4.0 Non-radiological
More informationInformed Consent for Columbia Combined Genetic Panel (CCGP) for Adults Please read the following
Informed Consent for Columbia Combined Genetic Panel (CCGP) for Adults Please read the following form carefully and discuss with your ordering physician/genetic counselor before signing consent. 1. The
More informationMINISTRY OF HEALTH OF THE RUSSIAN FEDERATION (Minzdrav of Russia) Moscow
1 MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION (Minzdrav of Russia) ORDER 9 January 2014 No. 2n Moscow On Approval of the Procedure for Medical Device Conformity Assessment in the Form of Technical Trials,
More informationCOOPERATIVE RESEARCH AND EXTERNAL INVESTIGATORS
COOPERATIVE RESEARCH AND EXTERNAL INVESTIGATORS Table of Contents I. OHRP Guidance on Engagement of Institutions in Human Subjects Research... 2 II. External Investigators: The institution in question
More informationCancer Center Clinical Trials Office
STANDARD OPERATING PROCEDURE MANAGEMENT OF EXPANDED ACCESS & TREATMENT USE PROTOCOLS SOP#: 2.3 Original Approval Date: 8/27/15 Version#: 2.0 Current revision Date: 2/20/18 1.0 PURPOSE/BACKGROUND Expanded
More informationViews of a Clinical Study Report
Out-of-(CSR)-Body Experiences Tips on Assembling Appendices, Datasets, and CRFs Susan C Sisk, PhD, RAC 1 Views of a Clinical Study Report OR Photos courtesy of Leigh Vaughan and RAPS, 2008 2 Topics Process
More informationNIH Guidelines for Recombinant and Synthetic Nucleic Acid Molecules Course (BIO305) Material
Introduction Welcome to the National Institutes Health (NIH) Guidelines for Recombinant and Synthetic Nucleic Acid Molecules (BIO305) Course. The ultimate goal of this course is to help all Principal Investigators
More informationSWOG Subject: Requests for Patient Data Original Release Date: April 2006 Departments Affected: All Revision Date: May 2013
SWOG http://swog.org Page 1 of 5 pages Original Release Date: April 2006 Departments Affected: All Revision Date: May 2013 REQUESTS FOR PATIENT DATA FROM SWOG STUDIES 1. Introduction...1 2. Data Sharing...2
More informationPolicy Appendix IV: DRCR.net Industry Collaboration Policies Version 6.0, August 2, 2017
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 DRCR.net is committed to: performing rigorous multi-center clinical
More informationTEST REQUISITION, PATIENT INFORMATION, AND CONSENT HUDSONALPHA CLINICAL SERVICES LAB
1. Patient Information Patient Name Last TEST REQUISITION, PATIENT INFORMATION, AND CONSENT HUDSONALPHA CLINICAL SERVICES LAB HUDSONALPHA CLINICAL SERVICES LAB CANNOT ACCEPT SAMPLES FROM FLORIDA, NEW YORK,
More informationLearning about Clinical Trials
Learning about Clinical Trials A Guide for Individuals and Their Loved Ones INTRODUCTION Clinical trials help researchers answer important medical questions, providing information that may help with the
More informationAUTHORIZATION TO USE AND DISCLOSE HEALTH INFORMATION
AUTHORIZATION TO USE AND DISCLOSE HEALTH INFORMATION I authorize the laboratory that has conducted or will conduct my genetic testing under the RPE65 Genetic Test Program and my physician to disclose to
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More informationAUTHORIZATION TO USE AND DISCLOSE HEALTH INFORMATION
AUTHORIZATION TO USE AND DISCLOSE HEALTH INFORMATION I authorize the laboratory that has conducted or will conduct my genetic testing under the RPE65 Genetic Test Program and my physician to disclose to
More informationCHECKLIST: Pre-review
11-5-2014 1 of 5 The purpose of this checklist is to provide support for IRB staff conducting pre-review. This checklist is to be completed by the IRB staff, signed, dated, and retained with the IRB protocol
More informationTEST REQUISITION, PATIENT INFORMATION, AND CONSENT HUDSONALPHA CLINICAL SERVICES LAB
1. Patient Information Patient Name Last TEST REQUISITION, PATIENT INFORMATION, AND CONSENT HUDSONALPHA CLINICAL SERVICES LAB HUDSONALPHA CLINICAL SERVICES LAB CANNOT ACCEPT SAMPLES FROM FLORIDA AND NEW
More informationIntroduction to Clinical Research
Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationTEST REQUISITION, PATIENT INFORMATION, AND CONSENT HUDSONALPHA CLINICAL SERVICES LABORATORY
1. Patient Information Patient Name TEST REQUISITION, PATIENT INFORMATION, AND CONSENT HUDSONALPHA CLINICAL SERVICES LABORATORY HudsonAlpha Clinical Services Lab, LLC HUDSONALPHA CLINICAL SERVICES LABORATORY
More information